Amgen (AMGN) Free Cash Flow (2009 - 2026)
Amgen (AMGN) posted quarterly Free Cash Flow of $1.5 billion for Q1 2026, up 50.71% year-over-year from $980.0 million in Q1 2025, and up 53.69% quarter-over-quarter from $961.0 million in Q4 2025.
Amgen (AMGN) Free Cash Flow (2009 - 2026) Analysis & Trends
Amgen's Free Cash Flow history runs 18 years deep, the most recent figure standing at $1.5 billion for Q1 2026.
- In Q1 2026, Free Cash Flow rose 50.71% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $8.6 billion (down 21.24% YoY), while the FY2025 annual figure was $8.1 billion, down 22.07% from the prior year.
- Free Cash Flow for Q1 2026 stood at $1.5 billion, up from $961.0 million in the prior quarter.
- The five-year high for Free Cash Flow was $4.4 billion in Q4 2024, with the low at $289.0 million in Q4 2023.
- The 5-year median for Free Cash Flow is $2.0 billion (2022), against an average of $2.1 billion.
- The sharpest annual moves came in 2023 and 2024: Free Cash Flow slumped 87.48% in 2023, then soared 1422.49% in 2024.
- Amgen's Free Cash Flow stood at $2.3 billion in 2022, then plunged by 87.48% to $289.0 million in 2023, then jumped by 1422.49% to $4.4 billion in 2024, then sank by 78.16% to $961.0 million in 2025, then surged by 53.69% to $1.5 billion in 2026.
- Business Quant data shows AMGN's Free Cash Flow at $1.5 billion in Q1 2026, $961.0 million in Q4 2025, and $4.2 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.30 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.11 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 4.48 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.56 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 302.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 440.07 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.49 Bn |
| Jun 30, 2026 | 3.49 Bn |
| Mar 31, 2026 | 1.48 Bn |
| Mar 31, 2026 | 1.48 Bn |
| Dec 31, 2025 | 961.00 Mn |
| Dec 31, 2025 | 961.00 Mn |
| Sep 30, 2025 | 4.25 Bn |
| Sep 30, 2025 | 4.25 Bn |
| Jun 30, 2025 | 1.91 Bn |
| Jun 30, 2025 | 1.91 Bn |
| Mar 31, 2025 | 980.00 Mn |
| Mar 31, 2025 | 980.00 Mn |
| Dec 31, 2024 | 4.40 Bn |
| Dec 31, 2024 | 4.40 Bn |
| Sep 30, 2024 | 3.31 Bn |
| Sep 30, 2024 | 3.31 Bn |
| Jun 30, 2024 | 2.22 Bn |
| Jun 30, 2024 | 2.22 Bn |
| Mar 31, 2024 | 459.00 Mn |
| Mar 31, 2024 | 459.00 Mn |